Login to Your Account



Financings Roundup

Affymax $50M+ Offering May Help Revive Peginesatide NDA

By Tom Wall


Monday, March 21, 2011
Affymax Inc. is reviving efforts to get FDA approval of peginesatide – previously known as Hematide – for treatment of anemia in chronic renal failure patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription